The latest announcement follows the recent US Food and Drug Administration (FDA) acceptance of the company’s new drug ...
Morgan Stanley expects the FDA to approve Gilead Sciences (NASDAQ:GILD)' Lenacapavir (LEN) for HIV prevention (PrEP) on or before its June 19 PDUFA date, a move that the bank believes could drive ...
A groundbreaking injectable designed to curb the global spread of HIV is now at risk of being delayed due to Donald Trump's ...
A multi-national, multi-institutional study led by Weill Cornell Medicine investigators found little natural resistance to a ...
US antivirals giant Gilead Sciences recently announced that the US Food and Drug Administration (FDA) has accepted its New ...
Foster City, California Tuesday, February 25, 2025, 16:00 Hrs [IST] ...
Lenacapavir, a twice yearly injection that prevents HIV transmission, was named the breakthrough medicine of 2024. But without US foreign aid dollars, its delivery to millions worldwide is under ...
When Jeep owners complained ads were appearing while driving, the carmaker said it was a glitch. But as auto makers consider ...
6d
News Medical on MSNNew HIV therapy lenacapavir shows high efficacy in Ugandan populationA multi-national, multi-institutional study led by Weill Cornell Medicine investigators found little natural resistance to a ...
Three bovine veterinarians had undetected H5N1 avian influenza infections despite no apparent contact with infected cows, ...
Gilead (GILD) announced that the European Medicines Agency has validated for parallel accelerated review the company’s marketing authorization ...
Lenacapavir is a twice-yearly injectable medication designed to be used as pre-exposure prophylaxis (PrEP). The FDA is giving ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results